Clinical Trials Browser

Phase 2 × OTHER × BMS-813160 × Clear all

NCT04123379 2025-01-17

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Phase 2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular